Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Utilizing B-Cells to Promote Glioblastoma Immunity
Clinical Breakthroughs

Utilizing B-Cells to Promote Glioblastoma Immunity

By Melissa RohmanOct 7, 2020
Share
Facebook Twitter Email
Catalina Lee Chang, PhD, research assistant professor of Neurological Surgery, was the first author of the study published in the Journal of Experimental Medicine.

Northwestern investigators have developed a novel vaccine that utilizes a specialized group of B-cells to promote anti-tumor immunity against glioblastoma, according to findings published in the Journal of Experimental Medicine.

The vaccine, which is still in pre-clinical stages, is the first of its kind and may be an alternative to currently available immunotherapeutic approaches to treat the fatal brain cancer, according to Catalina Lee Chang, PhD, research assistant professor of Neurological Surgery and first author of the study.

Glioblastoma, the most aggressive type of brain cancer, can occur at any age but most commonly develops in adults. The cancer has no cure and life expectancy after diagnosis can range anywhere between 12 to 24 months, depending on the timing and frequency of treatment.

Over the last 30 years, immunotherapy has become an effective option in helping the immune system fight various types of cancer. Unfortunately, however, most patients with glioblastoma have not benefited from this type of therapy.

“In the last hundred years, there have only been four FDA approved treatments for glioblastoma. We still measure survival in months rather than years, so there is a desperate need to make scientific advances,” said Maciej Lesniak, MD, chair and the Michael J. Marchese Professor of Neurosurgery and senior author of the study.

According to Lesniak, most immunotherapy research has historically focused on T-cells — immune cells that promote adaptive, long-term immunity against viral pathogens and cancer cells. However, previous work regarding B-cells, which support long-term immunity and can also produce antibodies to kill cancer cells, show more promise.

Maciej Lesniak, MD, chair and the Michael J. Marchese Professor of Neurosurgery, was senior author of the study.

“B-cells can function in many different ways, and certainly can be used a powerful tool to fight cancer by increasing anti-tumor immunity” Lee Chang said.

Putting this to the test, Lee Chang and co-investigators developed a vaccine based on a subpopulation of highly activated B-cells called 41BBL+ B-cells. The team then tested the vaccine in mouse models of glioblastoma, which traveled to lymphoid organs in the mice and promoted the anti-tumor function of CD8T cells, a specialized type of cytotoxic T-cells that attack and kill cancer cells.

Additionally, the B-cells also produced antibodies that bound to the glioblastoma cells, stimulating an immune response and ultimately preventing the growth of new tumors.

“With this vaccine, we are targeting the dual functionality of B-cells to tackle tumor immunosurveillance escape. We aim to utilize both the cellular and humoral immunity of B-cells,” Lee Chang said.

Currently, Lee Chang is collaborating with Northwestern Medicine investigators, including Roger Stupp, MD, the Paul C. Bucy Professor of Neurological Surgery and chief of Neuro-oncology in the Ken and Ruth Davee Department of Neurology, to develop a phase I clinical trial for the vaccine. She said she hopes the vaccine will be able to effectively “awaken” the immune system of glioblastoma patients, which is already severely compromised.

“There is no other vaccine of this kind out there. To have some sort of a footprint in the CD8T cell compartment, once we test this vaccine, will be the real victory,” Lee Chang said.

Lee Chang, Lesniak and Stupp are also members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

This study was supported by the National Institutes of Health grants P50CA221747, R35CA197725, R01NS093903, R01NS087990, and a National Cancer Institute Specialized Program of Research Excellence (SPORE) grant.

The National Cancer Institute’s five-year SPORE grant supports the advancement of translational research and improve outcomes for patients with brain cancer. The Lurie Cancer Center, one of six programs in the U.S. to have received the competitive grant, is leading a brain cancer SPORE with a special emphasis on glioblastoma.

Cancer Immunology Neurosurgery Patient Care Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Comments are closed.

Latest News

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
pride7
pride6
pride5
pride4
pride3
pride2
pride1
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.